Global Search

Hide Filters

Showing 1416 results

Press release / Sep 20, 2017

Novartis drug Rydapt® (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)

Significant overall survival benefit seen with Rydapt, the first targeted treatment for newly diagnosed FLT3-mutated AML approved in the EU[1] As the first and only therapy for advanced SM…
Press release / Jan 19, 2015

Novartis Cosentyx(TM) is the first IL-17 inhibitor to receive EU approval for first-line treatment of moderate-to-severe psoriasis patients

Cosentyx is the only biologic that can be used as first-line systemic therapy in the treatment of psoriasis and as an alternative to treatments that have significant side effects[1]; all other…
Press release / Jul 07, 2015

Novartis' new heart failure medicine LCZ696, now called Entresto(TM), approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization

First in the world approval brings hope of longer life and fewer hospitalizations for millions of Americans with heart failure with reduced ejection fraction Entresto is the first and only treatment…
Press release / Sep 12, 2018

Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with MS

Treatment with Gilenya (fingolimod) substantially reduced the debilitating impact of MS, with significant decreases in key measures of disease activity vs. interferon beta-1a MS severely affects…
Press release / Jan 31, 2018

Novartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah(TM) in children, young adults with r/r ALL

Analysis of 75 patients with median follow-up of more than a year demonstrated an overall remission rate of 81% Event-free survival and overall survival at six months were 73% and 90%, with…
Press release / Oct 19, 2018

Novartis announces presentation of new Lutathera® NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden

Lutathera treatment was associated with an ~80% reduction in the estimated risk of tumor progression or death vs comparator, regardless of baseline liver tumor burden[1] Lutathera treatment was…
Press release / Sep 29, 2021

Novartis data show achieving complete control of chronic spontaneous urticaria (CSU) improves overall quality of life, as reported by patients

Data analysis shows that preventing the symptoms of CSU (achieving complete control) improves overall health-related quality of life (HRQoL); including sleep and work productivity, among other…
Press release / Nov 01, 2017

Novartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell disease

Primary results of pivotal KymriahTM Phase II JULIET study in relapsed/refractory DLBCL Post-hoc sub-analysis of crizanlizumab (SEG101, formerly SelG1) SUSTAIN trial evaluating time to…
Press release / Oct 08, 2019

Novartis data show more patients are completely symptom-free from chronic spontaneous urticaria with ligelizumab (QGE031) than Xolair® 300 mg

Results from a Phase IIb dose-finding study show an average complete response rate of 42% for doses 240 mg and 72 mg ligelizumab at Week 12 compared with 26% for those taking 300 mg Xolair’s dose (…
Press release / Apr 21, 2020

Novartis announces new Mayzent® (siponimod) data show sustained effect in delaying disability for up to five years in patients with secondary progressive multiple sclerosis (SPMS)

New long-term data from EXPAND show patients with SPMS continuously treated with Mayzent® (siponimod) experienced lower risk of disability progression and cognitive decline than patients who delayed…

‹ Previous page
1
…
67
68
69
70
71
72
73
…
142
› Next page